Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System.

Current cancer drug targets - 1 Jan 2015

Han Xiaohong, Liu Manjiao, Wang Shuai, Lv Guanting, Ma Li, Zeng Changqing, Shi Yuankai

Abstract excerpt

The epidermal growth factor receptor-tyrosine kinase inhibitors (EGFRTKI), such as gefitinib and erlotinib have improved the survival of patients with nonsmall cell lung cancer (NSCLC). Unfortunately, acquired resistance will eventually develop in most patients who initially respond to the therap...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosome Mapping

Share to Drug Resistance, Neoplasm

Share to Gefitinib

Share to Lung Neoplasms

Share to Quinazolines

Source

Identifiers

PMID: 25877381
DOI: 10.2174/1568009615666150416122422

Genes

BAD
EGFR
FAS
FOXM1
FOXO3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25877381-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System.PMID 25877381Read ↗

Identification of a gefitinib resistance-associated signature for predicting prognosis and therapeutic response in lung adenocarcinoma via integrated multi-omics analysis and machine learningSemantic proximity Read ↗

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.Semantic proximity Read ↗

<i>SIRT2, TFEB, CNIH3, ADRM1</i> , AND <i>TM9SF4</i> AS POTENTIAL BIOMARKERS OF RESISTANCE TO CRIZOTINIB AND POOR PROGNOSIS IN LUNG ADENOCARCINOMA: IMPLICATIONS FOR TARGETED THERAPY AND IMMUNOTHERAPYSemantic proximity Read ↗

[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].Semantic proximity Read ↗

Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.Semantic proximity Read ↗

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)Semantic proximity Read ↗

Bioinformatic identification of the potential afatinib drug resistance gene BIRC5 in non-small- cell lung cancerSemantic proximity Read ↗

Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.Semantic proximity Read ↗

FGL1 Regulates Acquired Resistance to Gefitinib by Inhibiting Apoptosis in Non-small Cell Lung CancerSemantic proximity Read ↗

Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cellsSemantic proximity Read ↗

Exploring the mechanism of non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.